[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-cancers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,80,107,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644324","phase-2-iparomlimab-and-tovorilimab-ql1706-combined-with-bevacizumab-and-chemotherapy-as-neoadjuvant-therapy-for-advanced-ovarian-cancer-100644324",false,"NCT07663513","Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer","Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer: A Prospective, Single-Arm, Phase II Study","Inclusion Criteria:\n\n* Female, aged 18-75 years.\n* Histologically confirmed high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal adenocarcinoma.\n* FIGO stage III-IV unresectable ovarian cancer.\n* Life expectancy ≥16 weeks.\n* No prior anti-tumor therapy, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Adequate organ function, with laboratory test results meeting the following requirements:Hemoglobin (Hb) ≥90 g\u002FL; Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; Platelet count (PLT) ≥100×10⁹\u002FL; Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (or ≤5×ULN in patients with liver metastases); Serum creatinine clearance (CrCl) \\>50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Coagulation function: international normalized ratio (INR) ≤1.5×ULN and activated partial thromboplastin time (APTT) ≤1.5×ULN.\n* The subject agrees to use effective contraceptive measures from the signing of the informed consent form until 120 days after the last dose of the study drug. Female subjects of childbearing potential (15-49 years) must have a negative urine pregnancy test within 7 days before the start of treatment and must not be lactating. A female patient is considered to be of childbearing potential if she has menstruated, has not reached a postmenopausal state (defined as ≥12 consecutive months of amenorrhea for reasons other than menopause), and has not undergone sterilization surgery (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).\n* No contraindications for surgery.\n* The subject voluntarily participates in this study, signs the informed consent form, is compliant with the protocol, and cooperates with follow-up.\n\nExclusion Criteria:\n\n* Non-epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (e.g., germ cell tumors), as well as ovarian tumors of low malignant potential (e.g., borderline ovarian tumors).\n* Prior immunotherapy, including immune checkpoint inhibitory antibodies (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies, etc.), immune checkpoint agonistic antibodies (e.g., anti-ICOS, anti-CD40, anti-CD137, anti-GITR, anti-OX40 antibodies, etc.), and immune cell therapy.\n* Known hypersensitivity to large molecule protein preparations. Contraindications or allergy to any component of iparomlimab and tovorilimab (QL1706), paclitaxel, or carboplatin.\n* Major surgery (excluding diagnostic laparoscopy; local surgical treatment of isolated lesions is acceptable) within 28 days before the first dose.\n* History of allogeneic tissue\u002Fsolid organ transplantation.\n* Presence of a condition requiring systemic corticosteroids (\\>10 mg prednisone equivalent per day) or other immunosuppressive agents (e.g., cyclophosphamide, azathioprine, methotrexate, thalidomide, TNF-α inhibitors, etc.) within 2 weeks before the first dose. Topical corticosteroids, nasal sprays, and inhaled steroids are permitted. Systemic corticosteroids for the prevention of contrast media allergy are allowed.\n* Active or potentially recurrent autoimmune disease, with the following exceptions: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism due to autoimmune thyroiditis requiring only stable hormone replacement therapy; type I diabetes mellitus requiring only stable insulin replacement therapy.\n* Other active malignancies within the past 5 years, except for locally curable cancers that have been cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast), and breast cancer that has not recurred for \\>3 years after radical surgery.\n* History of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n* Symptomatic, untreated, or clinically unstable brain metastases or leptomeningeal metastases.\n* Hypertension (systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>100 mmHg) or diabetes that remains poorly controlled despite standard treatment; uncontrolled or symptomatic arrhythmia.\n* Thromboembolic events (e.g., cerebrovascular accident, including transient ischemic attack, cerebral hemorrhage, cerebral infarction, or pulmonary embolism) within 6 months before the start of study treatment.\n* Myocardial infarction, severe\u002Funstable angina pectoris, or symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV) within the past 12 months.\n* HIV-positive patients; HBsAg-positive with HBV DNA ≥2000 IU\u002FmL or ≥10⁴ copies\u002FmL; HCV antibody-positive with detectable HCV RNA.\n* Participation in another clinical trial within the previous 60 days or during the study treatment period.\n* Any other condition that, in the investigator's judgment, may interfere with the conduct of the study or the interpretation of the results. Other circumstances deemed by the investigator to make the patient unsuitable for enrollment.","FEMALE","18 Years","75 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single-center, single-arm clinical study to evaluate the efficacy and safety of iparomlimab and tovorilimab (QL1706) combined with paclitaxel, carboplatin, and bevacizumab as neoadjuvant therapy for advanced ovarian cancer.",[27],"Ovarian Cancers","NOT_YET_RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2029-04",{"name":38,"class":39},"Fudan University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100609796","phase-2-study-to-evaluate-the-diagnostic-performance-of-geh300079-68ga-injection-petct-for-detection-of-pc-in-patients-with-colorectal-gastric-ovarian-or-pancreatic-cancers-periscope-100609796","NCT07219238","Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET\u002FCT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","A Phase 2\u002F3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)\u002FComputed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","Inclusion Criteria:\n\n* Participant is ≥18 years of age\n* Participant has provided signed informed consent before any study-specific screening procedures\n* Participant has histopathologically confirmed primary colorectal, gastric or ovarian cancer or PDAC\n* Participant has known or suspected PC from the tumor of origin. Suspicion may be based on imaging or clinical findings.\n* Participant is scheduled for peritoneal surgery with curative intent, surgical exploration, or laparoscopy, with either: a. No neoadjuvant treatment received, treatment-naïve (i.e., undergoing upfront surgery or laparoscopy) b. Completed systemic treatment (which may include neoadjuvant chemotherapy) before GEH300079 ( 68Ga) PET\u002FCT Imaging Visit\n* Participant has Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* Participant is able and willing to comply with all study procedures as described in the protocol\n\nExclusion Criteria:\n\n* Participant is pregnant or breast-feeding, or sexually active and not using or not willing to use an acceptable form of birth control from screening up to 30 days after receiving the investigational medicinal product (IMP)\n* Participant has a known disorder that, in the opinion of the investigator, will impact the study procedures\n* Participant needs any intervention that would delay study participation\n* Participant has non-resectable extra-abdominal metastasis and\u002For \\>3 hepatic metastases on standard work up\n* Participant will not be able to complete the study, based on their anticipated life expectancy\n* Participant has active bacterial, viral, or fungal infection requiring systemic antibacterial, anti-viral or antifungal therapy (topical medications are permitted)\n* Participant has renal function impairment as defined by:\n\n  1. For Phase 2: estimated glomerular filtration rate less than 60 mL\u002Fmin\n  2. For Phase 3: estimated glomerular filtration rate less than 30 mL\u002Fmin\n* Participant has severe hepatic function impairment as defined by:\n\n  1. Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) and alanine aminotransferase (serum glutamic-pyruvic transaminase): ≤2.5 × upper limit of normal (ULN; ≤5 × ULN for participants with liver metastases)\n  2. Bilirubin: ≤1.5 × ULN or direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n* Participant has autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed\n* Participant has serious co-morbidities or serious non-malignant disease that in the opinion of the investigator, could compromise participant safety and\u002For protocol objectives\n* Participant either received or is planning to receive any other investigational agent within the 28 days prior to the first imaging visit or during study participation (with the exception of the 3-month follow-up period)\n* Participant has known or suspected hypersensitivity to any excipients used in GEH300079 (68Ga)\n* Participant has severe claustrophobia, is unable to lie flat or fit into the scanner, or is unable to tolerate the PET\u002FCT scan for any reason\n* (Phase 3 only) Participant was previously included in Phase 2 of this study","ALL",{"count":50,"type":21},175,[24,52],"PHASE3","This study is a Phase 2\u002F3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET\u002FCT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET\u002FCT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study.\n\nThe study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET\u002FCT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET\u002FCT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.",[55,56,27,57],"Colorectal Cancer","Gastric Cancers","Pancreatic Ductal Adenocarcinoma",[59,60,61,62,63,64,65,66,67,68],"Peritoneal Carcinomatosis (PC)","Pancreatic Cancers","Colorectal cancer","Gastric cancer","FAPI","Ovarian cancer","68Ga","PET\u002FCT imaging","Diagnostic imaging","Diagnostic performance","RECRUITING","2026-06-16",{"date":29,"type":32},{"date":73,"type":21},"2026-10",{"date":75,"type":21},"2029-08",{"name":77,"class":78},"GE Healthcare","INDUSTRY",2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":40},"100624270","phase-2-iparomlimab-and-tuvonralimab-ql1706-combined-with-standard-chemotherapy-or-combined-with-intraperitoneal-perfusion-chemotherapy-and-olaparib-as-neoadjuvant-therapy-for-advanced-ovarian-cancer-100624270","NCT07407452","Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer","A Prospective, Open-label, Multicenter Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer","Inclusion Criteria:\n\n* Participants voluntarily join this study, sign the informed consent form, and strictly comply with the protocol requirements;\n* Female patients aged between 18 and 75 years;\n* Patients who have undergone open surgery, laparoscopic surgery, or core needle aspiration biopsy, and have been histopathologically confirmed as having epithelial ovarian cancer (high-grade serous adenocarcinoma, endometrioid adenocarcinoma), peritoneal cancer, or fallopian tube cancer, FIGO 2018 Stage III-IV;\n* Meet the indications for neoadjuvant chemotherapy in ovarian cancer: ① Preoperative assessment by gynecologic oncologists (with multidisciplinary consultation when necessary) indicates low likelihood of achieving R0 resection with primary debulking surgery; ② Physical condition unable to tolerate PDS, unsuitable for immediate surgery (e.g., high perioperative risk, advanced age, medical comorbidities, etc.); ③ No prior systemic anti-tumor treatment for ovarian cancer (including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy); Note: Lymph node dissection or biopsy performed for clinical staging purposes after obtaining histopathology via needle biopsy, laparoscopic exploration, or other methods is permitted;\n* Accept BRCA1\u002F2 genetic mutation or HRD testing;\n* Presence of at least one measurable lesion according to RECIST 1.1 criteria;\n* Expected survival time ≥12 weeks;\n* ECOG score 0-1 (for Cohort 1), ECOG score 2 (for Cohort 2);\n* Adequate organ function, including:\n\nBone marrow function: Absolute neutrophil count ≥1,500\u002FμL; Platelets ≥100,000\u002FμL; Hemoglobin ≥10 g\u002FdL Hepatic function: Total bilirubin ≤1.5× upper limit of normal (ULN) or direct bilirubin ≤1.0× ULN; AST and ALT ≤2.5× ULN; Must be ≤5× ULN when liver metastases are present Renal function: Serum creatinine ≤1.5× ULN, or creatinine clearance ≥60 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n\n* Participants of childbearing potential must use appropriate contraceptive methods during the study period and for 120 days after study completion, have a negative serum pregnancy test within 7 days before study enrollment, and must be non-lactating participants.\n\nExclusion Criteria:\n\n* Non-epithelial origin ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (e.g., germ cell tumors); ovarian tumors of low malignant potential (e.g., borderline tumors);\n* Concurrent use of other cancer neoadjuvant therapies during this study, including but not limited to chemotherapy, radiotherapy, immunotherapy, microbial therapy, traditional Chinese medicine, and other experimental therapies;\n* Hypersensitivity to the active or inactive ingredients of the investigational drug or drugs with similar structure to the investigational drug;\n* Inability to swallow oral medications and any gastrointestinal disorders that may interfere with the absorption and metabolism of study drugs (for Cohort 2);\n* Prior treatment with known or suspected poly (ADP-ribose) polymerase (PARP) inhibitors (for Cohort 2);\n* Presence of symptomatic or uncontrolled brain metastases requiring concurrent treatment;\n* Active or potentially recurrent autoimmune disease; exceptions include: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism caused by autoimmune thyroiditis requiring only stable dose hormone replacement therapy; Type 1 diabetes requiring only stable dose insulin replacement therapy;\n* Major surgery within 3 weeks before study initiation, or incomplete recovery from surgery;\n* History of organ transplantation, autologous\u002Fallogeneic stem cell transplantation;\n* Known or self-reported human immunodeficiency virus (HIV) infection;\n* HBV-DNA positive, HCV-DNA positive (copy number \\>10³);\n* Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40, etc.), immune cell therapy, or any other treatments targeting tumor immune mechanisms;\n* Live vaccine administered within 4 weeks before first dose, or planned live vaccine administration during the study period;\n* History of other malignancies within the past 3 years, except for cutaneous squamous cell carcinoma, basal cell carcinoma, ductal carcinoma in situ of the breast, or cervical carcinoma in situ;\n* Prior or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);\n* Patients who received platelet or red blood cell transfusions within 4 weeks before initiation of study drug treatment;\n* Pregnant, lactating, or patients planning to become pregnant during study treatment;\n* Patients deemed unsuitable for participation in this study by the investigator.",{"count":88,"type":21},50,[24],"This study is a prospective, open-label, multicenter Phase II clinical trial, planning to enroll 50 patients with advanced ovarian cancer. Enrolled participants will be assigned to 2 cohorts based on ECOG performance status and genetic mutation status:\n\nCohort 1: ECOG PS 0 or 1, all-comers population, regardless of BRCA or HRD test results. Treatment: iparomlimab and tuvonralimab (5 mg\u002Fkg, Q3W, D1) + paclitaxel (175 mg\u002Fm², Q3W, D1) + carboplatin (AUC 5-6, Q3W, D1)\u002Fcisplatin (75 mg\u002Fm², Q3W, D1). Planned enrollment: 30 patients.\n\nCohort 2: ECOG PS 2, BRCA1\u002F2 mutation or HRD positive. Treatment: iparomlimab and tuvonralimab (5 mg\u002Fkg, Q3W, D1) + olaparib (300 mg, for 2-3 cycles, bid) + intraperitoneal perfusion (cisplatin, 75 mg\u002Fm², Q3W, D1). Planned enrollment: 20 patients.\n\nNeoadjuvant therapy will be administered for 3 cycles, followed by patient status assessment. Patients with CR\u002FPR\u002FSD will be allowed to undergo surgery, while PD patients will have subsequent treatment strategies determined by the investigator.",[27],[93,94,95,96,97],"ovarian cancer","ICIs","Neoadjuvant therapy","QL1706","olaparib","2026-02-10",{"date":100,"type":32},"2026-02-12",{"date":102,"type":21},"2026-02-01",{"date":104,"type":21},"2028-12-31",{"name":106,"class":39},"Jiangsu Cancer Institute & Hospital",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":40},"100579527","early-phase-1-allogeneic-b7h3-car-t-cell-therapy-for-advanced-solid-tumors-100579527","NCT06825455","Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors","Clinical Study of the Safety and Tolerability of B7H3 CAR-γδT Cell Injection in the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years old, gender is not limited;\n2. Expected survival time ≥3 months;\n3. ECOG score 0\\~1;\n4. Patients who meet the clinical diagnostic criteria and have a clear pathological diagnosis of malignant solid tumors that have failed standard treatment;\n5. Tumor tissue samples (specimens within one year are recommended) positive for B7H3 by immunohistochemical (IHC) staining or flow assay;\n6. Presence of at least one evaluable lesion according to RECIST V1.1;\n7. Tumors limited to peritoneal (metastatic) and ovarian cancer in patients in the laparotomy group;\n8. Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before the first treatment with cell injection):\n\n   Blood: white blood cell count (WBC) ≥3E9\u002FL, lymphocyte count (LY) ≥0.8E9\u002FL, hemoglobin (Hb) ≥80g\u002FL, platelet (PLT) ≥75E9\u002FL; Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; total bilirubin ≤ 3.0 × ULN; Kidney: serum creatinine ≤ 1.5 × upper limit of normal range (ULN); Heart: left ventricular ejection fraction ≥50% on echocardiography; lung: normal oxygen saturation without oxygen.\n9. Pregnancy test should be negative for women of childbearing potential and both men and women agree to use effective contraception during treatment and for 1 year thereafter;\n10. Be able to understand the requirements and matters of the trial and be willing to participate in the clinical study as required;\n11. Sign the trial informed consent form.\n\nExclusion Criteria:\n\n1. Known hypersensitivity, allergy, intolerance, or contraindication to cell infusion or any of the drug components that may be used in the study, including fludarabine and cyclophosphamide;\n2. Patients who have been continuously using immunosuppressive drugs within 1 month prior to cell infusion;\n3. Cerebrovascular accident or seizure within 6 months prior to signing the informed consent form;\n4. Symptomatic brain metastases;\n5. a known psychiatric or substance abuse disorder that would interfere with cooperation with the trial requirements;\n6. Hepatitis B surface antigen (HBsAg) positivity or hepatitis B core antibody (HBcAb) positivity and a peripheral blood test for hepatitis B virus (HBV) DNA titer that is not within the normal reference range; hepatitis C virus (HCV) antibody positivity and peripheral blood hepatitis C virus (HCV) RNA positivity; human immunodeficiency virus (HIV) antibody positivity; syphilis Positive for syphilis;\n7. Serious cardiac disease: including, but not limited to, unstable angina pectoris, myocardial infarction (occurring within 6 months prior to screening), congestive heart failure (NYHA classification ≥ III), and severe arrhythmias;\n8. Presence of active or uncontrolled infections requiring systemic therapy (except for mild genitourinary and upper respiratory tract infections);\n9. has not recovered from acute toxic effects of prior therapy (prior therapy-induced hematologic or organ toxicity ≥ Grade 2, except for abnormalities related to study disease and medical history);\n10. have a confirmed diagnosis of an immunodeficiency\n11. suffering from an active infection requiring systemic therapy;\n12. a female subject of childbearing potential who plans to become pregnant within 2 years of cell infusion; or a male subject whose partner plans to become pregnant within 2 years of cell infusion;\n13. Participation in a clinical study of another innovative drug within 1 month prior to screening;",{"count":115,"type":21},18,[117],"EARLY_PHASE1","γδT cells can directly recognize non-peptide tumor antigens, such as IPP phosphorylated metabolites, without relying on specific major histocompatibility complexes (MHCs). This unique characteristic leads to a lower risk of graft-versus-host disease (GVHD). The clinical safety of γδT cells in allogeneic tumor therapies has been validated multiple times, highlighting their significant potential in developing universal CAR-T cell therapies.\n\nB7H3 (CD276), a member of the B7 negative co-stimulatory molecule family, is minimally expressed or absent in normal tissues but highly expressed in various tumor tissues. As a result, B7H3 is regarded as a highly promising tumor-associated antigen and a universal drug target with substantial therapeutic potential.\n\nBy utilizing γδT cells as carrier cells, the development of universal B7H3 CAR-γδT cell injections for advanced solid tumors can effectively address risks such as autologous cell preparation failure and treatment delays. This innovative approach offers a highly efficient solution for solid tumor treatment and holds great promise for advancing immunotherapy in this field",[120,27,121],"Advanced Solid Tumors","Peritoneal (metastatic) Cancer",[123,124,125],"cell therapy","γδT","CAR-T","2025-02-09",{"date":128,"type":32},"2025-02-13",{"date":130,"type":21},"2025-03-01",{"date":132,"type":21},"2027-12-31",{"name":134,"class":39},"Peking University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":40},"100336975","genetic-predisposition-to-breast-and-ovarian-cancer-prospective-study-of-brcax-gene-mutation-100336975","NCT03667417","Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation","GENEPSO","1. Woman or man, with or without cancer, carrying a deleterious BRCA1\u002FBRCA2 mutation, aged 18 years and over.\n\n   1. Woman with or without breast cancer or ovarian cancer at baseline.\n   2. Man with or without breast cancer at baseline.\n2. Signed consent to participation\n3. Affiliation to a social security regimen, or beneficiary of such a regimen.\n\nExclusion Criteria:\n\n1. A person of legal age subject to a legal protection measure, or unable to express consent.\n2. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons",true,{"count":144,"type":21},5000,"OBSERVATIONAL","Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers",[148,27],"Breast Cancers",[150],"BRCA gene mutation","2020-06-30",{"date":153,"type":32},"2020-07-01",{"date":155,"type":32},"1999-10-15",{"date":157,"type":21},"2028-10-15",{"name":159,"class":39},"Institut Paoli-Calmettes"]